The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Improving Aboriginal Children's Access To Better Ear And Hearing Health Through Telehealth ENT
Funder
National Health and Medical Research Council
Funding Amount
$1,123,450.00
Summary
Aboriginal children experience the highest rates of chronic ear disease in the world, with access to specialist ENT care limited by cultural issues as well as long travel distances, if they live in rural areas. This results in children developing hearing loss that could have been prevented with early childhood ENT treatment. This Indigenous led telehealth research, based in NSW, will create an efficient, culturally appropriate hearing health care model for all Indigenous Australians.
Integration Of Novel Biological Targets/biomarkers In The Treatment Of Lethal Prostate Cancer
Funder
National Health and Medical Research Council
Funding Amount
$1,930,260.00
Summary
Prostate cancer (PC) remains a major cause of cancer-related death. Precision medicine is predicated on the principle of the right drug for the right patient at the right time. This program aims to assess/validate the ability of blood-based molecular markers to predict an individual patient’s response to different treatments and develop new drug strategies based on biological endpoints. Overall, this project has the potential to improve survival and quality of life in men with lethal PC.